EGFR and non-small cell lung carcinoma: As the third most common activating mutations in epidermal growth factor receptor (EGFR), exon 20 insertions (20ins) comprise 10-12% cases in EGFR-addicted non-small-cell lung cancer (NSCLC)1–3.